Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis
by Gabrielle Capaldo
53.3% of pediatric patients treated with AB-101a achieved a 1-point decrease in IGA vs. 0% of those treated with vehicle.
This outcome was also seen in 60% of adults using the topical vs. 37.5% using vehicle.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195